Glaxo Gets FDA Nod for Nucala for Hypereosinophilic Syndrome
GlaxoSmithKline plc GSK announced that the FDA has approved its drug, Nucala for a new indication hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.
Nucala, an anti-IL5 biologic, is presently marketed for eosinophil-driven diseases like severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. Also an eosinophil-driven disease, HES is the third indication for which it is now approved in the United States. Nucala is the first and only targeted biologic treatment to be approved for HES.
The FDA approval was based on positive data from a pivotal phase III study, which showed that when given Nucala, 50% fewer patients experienced a HES flare, over the 32-week study period, compared to placebo when added to standard-of-care treatment. HES patients suffer from debilitating flares and reducing them is the treatment goal of such medicines.
So far this year, Glaxo’s shares have declined 19.5% compared with the industry’s 1% decline.
Nucala is a key drug in Glaxo’s portfolio of new respiratory drugs. The drug’s sales of £451 million in first half of 2020 registered around 28% growth at constant exchange rate. Nucala is being evaluated in a late-stage study for COPD. Meanwhile, Glaxo expects to file regulatory submissions seeking approval of Nucala for chronic rhinosinusitis with nasal polyps (CRSwNP) indication this year
Potential approval for additional indications can strengthen the drug’s eligible patient population and boost sales in the future.
However, competitive pressure in the overall respiratory market has intensified with the launch of Regeneron REGN and Sanofi’s SNY blockbuster medicine, Dupixent and AstraZeneca’s AZN Fasenra. Dupixent now is approved in the United States and the EU for three type II inflammatory diseases, namely CRSwNP, severe asthma and moderate-to-severe atopic dermatitis. Fasenra is approved for severe eosinophilic asthma while being studied for HES and CRSwNP.
Glaxo currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Sanofi (SNY) : Free Stock Analysis Report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
